Durmus Burak Demirkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Durmus Burak Demirkaya has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Asena Pinar Sefer
Recep Tayyip Erdoğan University
1 shared publication - Burkay Cagan Colak
Marmara University
1 shared publication - Habibe Sema Arslan
Kirsehir Ahi Evran Universitesi
1 shared publication - Safa Baris
Marmara University
1 shared publication - Serap Yalcin
Kirsehir Ahi Evran Universitesi
1 shared publication
Latest Publications
- 3 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 159
Investigation of cytotoxic, molecular and in silico effects of chlorambucil and tamoxifen on 2D/3D MDA-MB-231 and HeLa cancer cell models
This study aimed to investigate the cytotoxic, morphological, and molecular effects of Tamoxifen (TMX) and Chlorambucil (CHL) on breast cancer (MDA-MB-231) and cervical cancer (HeLa) cell lines. The impact of these agents on metastatic behavior, apoptotic mechanisms, and gene expression profiles was examined in both two-dimensional (2D) and three-dimensional (3D) cell culture models. Cells were treated with varying concentrations of TMX and CHL. Cytotoxicity was assessed using the XTT assay, and morphological changes were monitored by microscopy. Migration and invasion assays assessed metastatic potential. VEGFA expression was quantified by qRT-PCR. In 3D cultures, treatment responses were evaluated based on size reduction and structural changes in hydrogel-based spheroids. Docking analysis was conducted to determine binding affinities of TMX and CHL. TMX and CHL exhibited dose-dependent effects on breast and cervical cancer cells. Combination treatment led to significantly greater reductions in cell viability compared to controls (p < 0.05). Moreover, VEGFA expression was markedly reduced in both 2D and 3D models (p < 0.05). These findings support the potential therapeutic value of TMX and CHL. Docking analysis revealed highly negative binding energies, consistent with in vitro results, indicating synergistic interaction at molecular and cellular levels. TMX and CHL combination therapy demonstrated potent anti-cancer activity in breast and cervical cancer models, reducing cell viability, metastatic capacity, and VEGFA expression. These results suggest that TMX and CHL, when used together, may represent a promising strategy for developing synergistic and targeted cancer therapies. Further in vivo and clinical validation is warranted.
- 3 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 159
Investigation of cytotoxic, molecular and in silico effects of chlorambucil and tamoxifen on 2D/3D MDA-MB-231 and HeLa cancer cell models
This study aimed to investigate the cytotoxic, morphological, and molecular effects of Tamoxifen (TMX) and Chlorambucil (CHL) on breast cancer (MDA-MB-231) and cervical cancer (HeLa) cell lines. The impact of these agents on metastatic behavior, apoptotic mechanisms, and gene expression profiles was examined in both two-dimensional (2D) and three-dimensional (3D) cell culture models. Cells were treated with varying concentrations of TMX and CHL. Cytotoxicity was assessed using the XTT assay, and morphological changes were monitored by microscopy. Migration and invasion assays assessed metastatic potential. VEGFA expression was quantified by qRT-PCR. In 3D cultures, treatment responses were evaluated based on size reduction and structural changes in hydrogel-based spheroids. Docking analysis was conducted to determine binding affinities of TMX and CHL. TMX and CHL exhibited dose-dependent effects on breast and cervical cancer cells. Combination treatment led to significantly greater reductions in cell viability compared to controls (p < 0.05). Moreover, VEGFA expression was markedly reduced in both 2D and 3D models (p < 0.05). These findings support the potential therapeutic value of TMX and CHL. Docking analysis revealed highly negative binding energies, consistent with in vitro results, indicating synergistic interaction at molecular and cellular levels. TMX and CHL combination therapy demonstrated potent anti-cancer activity in breast and cervical cancer models, reducing cell viability, metastatic capacity, and VEGFA expression. These results suggest that TMX and CHL, when used together, may represent a promising strategy for developing synergistic and targeted cancer therapies. Further in vivo and clinical validation is warranted.
- 3 August 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (8) , 1083-1100
The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies
The Janus kinase/signal transducer and activator of transcription signaling pathway orchestrates crucial aspects of immune regulation, including cytokine signaling, cellular proliferation, differentiation, and apoptosis. Dysregulation of this pathway due to gain- or loss-of-function mutations significantly contributes to the development of inborn errors of immunity and various immune-mediated disorders. Understanding the molecular basis of these abnormalities is fundamental for enhancing diagnostic precision and developing targeted therapies. A bibliographic search was conducted in PubMed and MEDLINE for articles published up to June 2025. The review offers a comprehensive overview of the structural and functional features of JAK/STAT family proteins, the intrinsic regulatory mechanisms, and the immunopathological consequences of STAT1, STAT3, and STAT6 GOF mutations. Recent clinical advances, particularly the therapeutic impact of JAK inhibitors and emerging novel molecules, are critically discussed, emphasizing the integration of molecular insights into clinical practice. Advances in the molecular characterization of JAK/STAT pathway dysregulation have opened new avenues for precision medicine approaches. While JAKinibs have shown promising outcomes, further research is needed to optimize therapeutic strategies, identify predictive biomarkers, and refine patient selection to maximize clinical benefits. Novel targeted therapies can reshape the management of JAK/STAT-related diseases in the coming years.
- 3 August 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (8) , 1083-1100
The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies
The Janus kinase/signal transducer and activator of transcription signaling pathway orchestrates crucial aspects of immune regulation, including cytokine signaling, cellular proliferation, differentiation, and apoptosis. Dysregulation of this pathway due to gain- or loss-of-function mutations significantly contributes to the development of inborn errors of immunity and various immune-mediated disorders. Understanding the molecular basis of these abnormalities is fundamental for enhancing diagnostic precision and developing targeted therapies. A bibliographic search was conducted in PubMed and MEDLINE for articles published up to June 2025. The review offers a comprehensive overview of the structural and functional features of JAK/STAT family proteins, the intrinsic regulatory mechanisms, and the immunopathological consequences of STAT1, STAT3, and STAT6 GOF mutations. Recent clinical advances, particularly the therapeutic impact of JAK inhibitors and emerging novel molecules, are critically discussed, emphasizing the integration of molecular insights into clinical practice. Advances in the molecular characterization of JAK/STAT pathway dysregulation have opened new avenues for precision medicine approaches. While JAKinibs have shown promising outcomes, further research is needed to optimize therapeutic strategies, identify predictive biomarkers, and refine patient selection to maximize clinical benefits. Novel targeted therapies can reshape the management of JAK/STAT-related diseases in the coming years.